AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events

REDWOOD CITY, Calif., Feb. 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. ACRX, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer will be presenting at RBC Capital Markets' Global Healthcare Conference and Cowen and Company's 35th Annual Healthcare Conference.  Details of the two presentations are as follows:

RBC Capital Markets' Global Healthcare Conference
Date: Tuesday February 24th
Location: The New York Palace Hotel
Presentation Time: 11:30am ET, 8:30am PT

Cowen and Company 35th Annual Healthcare Conference
Date:  Monday March 2nd
Location:  The Boston Marriott Copley Place
Presentation Time: 1:30 pm ET, 10:30am PT

Presentations will be webcast live and can be accessed through the Investors page at www.acelrx.com.  For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, Zalviso, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting and on July 25^th, 2014 received a Complete Response Letter from the FDA. AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting. The Company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-two-upcoming-investor-events-300038898.html

SOURCE AcelRx Pharmaceuticals, Inc.